Baiyunshan Pharmaceutical (00874) Sets 20 Mar 2026 Board Meeting to Approve FY2025 Audited Results

Bulletin Express

Mar 10

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (H share stock code: 00874) has scheduled a board meeting for Friday, 20 March 2026 in Guangzhou. The agenda includes consideration and approval of the audited consolidated financial results for the year ended 31 December 2025, along with any other relevant business.

The current Board configuration is as follows: • Executive directors: Li Xiaojun, Chen Jiehui, Cheng Hongjin, Tang Heping and Li Hong • Independent non-executive directors: Chen Yajin, Huang Min, Wong Lung Tak Patrick and Sun Baoqing

The company released the meeting notice on 10 March 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1123900438"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1123900438\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1123900438?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 16:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123900438","market":"us","top_or_hot":-1,"title":"Baiyunshan Pharmaceutical (00874) Sets 20 Mar 2026 Board Meeting to Approve FY2025 Audited Results","media":"Bulletin Express","content":"<p>Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (H share stock code: 00874) has scheduled a board meeting for Friday, 20 March 2026 in Guangzhou. The agenda includes consideration and approval of the audited consolidated financial results for the year ended 31 December 2025, along with any other relevant business.</p>\n<p>The current Board configuration is as follows:\n• Executive directors: Li Xiaojun, Chen Jiehui, Cheng Hongjin, Tang Heping and Li Hong  \n• Independent non-executive directors: Chen Yajin, Huang Min, Wong Lung Tak Patrick and Sun Baoqing</p>\n<p>The company released the meeting notice on 10 March 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baiyunshan Pharmaceutical (00874) Sets 20 Mar 2026 Board Meeting to Approve FY2025 Audited Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaiyunshan Pharmaceutical (00874) Sets 20 Mar 2026 Board Meeting to Approve FY2025 Audited Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-10 16:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (H share stock code: 00874) has scheduled a board meeting for Friday, 20 March 2026 in Guangzhou. The agenda includes consideration and approval of the audited consolidated financial results for the year ended 31 December 2025, along with any other relevant business.</p>\n<p>The current Board configuration is as follows:\n• Executive directors: Li Xiaojun, Chen Jiehui, Cheng Hongjin, Tang Heping and Li Hong  \n• Independent non-executive directors: Chen Yajin, Huang Min, Wong Lung Tak Patrick and Sun Baoqing</p>\n<p>The company released the meeting notice on 10 March 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00874","symbol_name":"白云山","start_time":0,"source_url":"","article_id":"1123900438","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123900438","pubTimestamp":1773132196,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (H share stock code: 00874) has scheduled a board meeting for Friday, 20 March 2026 in Guangzhou. The agenda includes consideration and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00874":"白云山"},"translate_title":"白云山药业(00874)定于2026年3月20日召开董事会批准2025财年经审核业绩","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00874":1},"content_text":"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (H share stock code: 00874) has scheduled a board meeting for Friday, 20 March 2026 in Guangzhou. The agenda includes consideration and approval of the audited consolidated financial results for the year ended 31 December 2025, along with any other relevant business.\nThe current Board configuration is as follows:\n• Executive directors: Li Xiaojun, Chen Jiehui, Cheng Hongjin, Tang Heping and Li Hong  \n• Independent non-executive directors: Chen Yajin, Huang Min, Wong Lung Tak Patrick and Sun Baoqing\nThe company released the meeting notice on 10 March 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}